<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03168841</url>
  </required_header>
  <id_info>
    <org_study_id>2014-26</org_study_id>
    <nct_id>NCT03168841</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients</brief_title>
  <official_title>Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western University of Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Onychomycosis, a common pathology of the toenails, is even more prevalent among diabetic
      subjects. Nearly 26 million Americans suffer from diabetes, and approximately one-third of
      subjects with diabetes have toenail onychomycosis. Numerous studies have addressed the
      efficacy and safety of both topical and oral antifungal treatment options for onychomycosis
      in diabetic subjects. However, no study to date has specifically addressed the efficacy and
      safety of efinaconazole among diabetic subjects.

      The objective of this noncomparative, uncontrolled study is to determine the efficacy of
      topical efinaconazole 10% for toenail onychomycosis among subjects with diabetes mellitus.
      Specific indicators to measure efficacy of treatment will be the mycological cure rate,
      complete cure rate, and treatment success. Furthermore, an additional goal of the study is to
      gain knowledge of safety in the setting of a cohort of diabetic subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2017</start_date>
  <completion_date type="Actual">January 9, 2019</completion_date>
  <primary_completion_date type="Actual">January 9, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Endpoint - Efficacy</measure>
    <time_frame>50 weeks</time_frame>
    <description>The primary efficacy end point is the proportion of subjects achieving complete cure at week 50. Complete cure is to be defined as a combination of 0% clinical involvement and mycological cure (mycological cure defined as negative KOH examination and negative fungal culture of the target toenail sample).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint - Efficacy</measure>
    <time_frame>50 weeks</time_frame>
    <description>The first secondary efficacy end point is mycological cure, defined as negative KOH examination and negative fungal culture of the target toenail sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint - Efficacy</measure>
    <time_frame>50 weeks</time_frame>
    <description>The second secondary efficacy end point is clinical cure, defined as 0% clinical involvement of the target toenail.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint - Safety (Occurrence of Adverse Events: Type and Frequency)</measure>
    <time_frame>50 weeks</time_frame>
    <description>The secondary safety endpoint is the occurrence of adverse events (type and frequency).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>Intervention Group, receiving medication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled subjects with confirmed onychomycosis will be dispensed topical medication for treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efinaconazole Topical</intervention_name>
    <description>Enrolled subjects will be dispensed medical for topical application, and followed for a period of 50 weeks.</description>
    <arm_group_label>Intervention Group, receiving medication</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of onychomycosis confirmed through positive KOH stain or positive
             mycologic culture findings.

          -  Involvement of at minimum 20% of the target great toenail.

        Exclusion Criteria:

          -  Diagnosis of a nondermatophyte fungus infection, diagnosis of proximal subungual
             onychomycosis, diagnosis of superficial white onychomycosis

          -  Diagnosis of peripheral arterial disease or anatomic abnormalities of the target
             toenail

          -  Inability to follow through with all requisite office visits

          -  Routine use of a systemic corticosteroid, routine use of a systemic immunomodulator,
             or history of systemic antifungals within the prior five years.

          -  Active interdigital tinea pedis refractory to topical antifungal treatments

          -  Known hypersensitivity to efinaconazole

          -  Use, within the month preceding screening, of: topical antifungal agents, topical
             anti-inflammatory agents to the toes

          -  Any history of oral systemic antifungal with known activity against dermatophytes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Western University of Health Sciences</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <results_first_submitted>October 1, 2019</results_first_submitted>
  <results_first_submitted_qc>October 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 23, 2019</results_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efinaconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT03168841/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention Group, Receiving Medication</title>
          <description>Enrolled subjects with confirmed onychomycosis will be dispensed topical medication for treatment.
Efinaconazole Topical: Enrolled subjects will be dispensed medical for topical application, and followed for a period of 50 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention Group, Receiving Medication</title>
          <description>Enrolled subjects with confirmed onychomycosis will be dispensed topical medication for treatment.
Efinaconazole Topical: Enrolled subjects will be dispensed medical for topical application, and followed for a period of 50 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.15" spread="9.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <category_list>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African-American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Endpoint - Efficacy</title>
        <description>The primary efficacy end point is the proportion of subjects achieving complete cure at week 50. Complete cure is to be defined as a combination of 0% clinical involvement and mycological cure (mycological cure defined as negative KOH examination and negative fungal culture of the target toenail sample).</description>
        <time_frame>50 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group, Receiving Medication</title>
            <description>Enrolled subjects with confirmed onychomycosis will be dispensed topical medication for treatment.
Efinaconazole Topical: Enrolled subjects will be dispensed medical for topical application, and followed for a period of 50 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Endpoint - Efficacy</title>
          <description>The primary efficacy end point is the proportion of subjects achieving complete cure at week 50. Complete cure is to be defined as a combination of 0% clinical involvement and mycological cure (mycological cure defined as negative KOH examination and negative fungal culture of the target toenail sample).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Endpoint - Efficacy</title>
        <description>The first secondary efficacy end point is mycological cure, defined as negative KOH examination and negative fungal culture of the target toenail sample.</description>
        <time_frame>50 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group, Receiving Medication</title>
            <description>Enrolled subjects with confirmed onychomycosis will be dispensed topical medication for treatment.
Efinaconazole Topical: Enrolled subjects will be dispensed medical for topical application, and followed for a period of 50 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Endpoint - Efficacy</title>
          <description>The first secondary efficacy end point is mycological cure, defined as negative KOH examination and negative fungal culture of the target toenail sample.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Endpoint - Efficacy</title>
        <description>The second secondary efficacy end point is clinical cure, defined as 0% clinical involvement of the target toenail.</description>
        <time_frame>50 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Endpoint - Safety (Occurrence of Adverse Events: Type and Frequency)</title>
        <description>The secondary safety endpoint is the occurrence of adverse events (type and frequency).</description>
        <time_frame>50 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention Group, Receiving Medication</title>
          <description>Enrolled subjects with confirmed onychomycosis will be dispensed topical medication for treatment.
Efinaconazole Topical: Enrolled subjects will be dispensed medical for topical application, and followed for a period of 50 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Application site vesicles, local</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Shofler</name_or_title>
      <organization>Western University of Health Sciences</organization>
      <phone>9097063898</phone>
      <email>dshofler@westernu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

